An 8-week treatment course with cilostazol as an adjunct to risperidone demonstrates a favourable safety and efficacy profile in patients with schizophrenia, improving primary negative symptoms without resulting in serious adverse events requiring medical intervention, a study has shown.
At least one dose of the 13-valent pneumococcal conjugate vaccine (PCV13) has high individual vaccine effectiveness (VE) in preventing invasive pneumococcal disease (IPD) in a paediatric population with suboptimal vaccination coverage, a new study has shown.
Both denosumab and bisphosphonates enhance bone mineral density (BMD) in men with nonmetastatic prostate cancer who are receiving androgen deprivation therapy (ADT), according to a systematic review and meta-analysis. In addition, denosumab lowers the risk for radiographic vertebral fractures.
The angiotensin converting enzyme inhibitor perindopril does not appear to improve postural sway in older individuals at risk of falls, according to a study. Despite the lack of effect on postural balance, the drug does not worsen the rate of falls or orthostatic hypotension.
The use of lithium treatment appears to be effective in patients with bipolar disorder with suspected suicidal intentions, according to a recent study. However, risk for suicide is only one of the many considerations when providing clinical care.
Use of proton pump inhibitors appears to pose an increased risk of first-time ischaemic stroke in the general population, irrespective of treatment with antiplatelet agents, according to a study. However, the magnitude of the said association is modest, and a cause-and-effect relationship remains to be established.
Treatment with the arginine vasopressin receptor 1A (V1a) antagonist, RG7713, induces subtle improvements in social communication surrogates including eye tracking and affective speech recognition, among others, in adults with high-functioning autism spectrum disorder (ASD), a study has shown.
Orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide were effective in achieving weight loss among overweight and obese adults at 52 weeks, a recent study found. Phentermine-topiramate and liraglutide were associated with the highest odds of achieving at least 5 percent weight loss.